MedTrace Logo

Associations Between Diabetes Care and Haptoglobin Genotype On outComes

NCT00872456 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3054

Last updated 2020-07-16

No results posted yet for this study

Summary

The ADHOC Cohort comprised 3044 DM individuals, treated in 47 CHS primary care clinics, that underwent haptoglobin genotyping between 2 march, 2005 and 26 September 2006. Individuals were eligible for inclusion if they had DM and were 55 years of age or older. All treatment decisions, regarding all aspects of care and follow-up of the study participants, remained at the discretion of the individual's primary care physician, who was blinded to the individual's Hp type. Hp distribution was: Hp 1-1 285 (9.4%); Hp 2-1 1248 (41.0%); Hp 2-2 1511 (49.6%).

Hypothesis: strict glucose control (HbA1c\<7%) reduces the rate of cardiovascular events only to diabetic patients with the Hp 2-2 phenotype. We also postulated that, since Hp 2-2 DM individuals are at an increased genetic susceptibility for cardiovascular disease (CVD), this unique cohort merits an investigation on the associations between various CVD risk variables and CVD events and establish whether any evident association was dependent of the individual's Hp type.

Conditions

Sponsors & Collaborators

  • Clalit Health Services

    lead OTHER

Principal Investigators

  • Uzi Milman, MD · Clalit Health Services, Haifa and Western Galilee District, Haifa, Israel.

  • Chen Shapira, MD · Carmel Medical Center, Clalit Health Services

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2020-07-15
Completion
2020-07-15

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00872456 on ClinicalTrials.gov